HRD Genetic Testing Provides Access to Targeted Therapies for 50% of Ovarian Cancer Patients

SOFIVA Genomics (6615) held its earnings call today (15^th), reporting a 4.38% growth from January to November compared to the same period last year and strong R&D momentum despite the pandemic. The Company further expressed its commitment in the new year (2022) to continue deepening and broadening its precision medicine capacity to meet the diverse needs of the cancer market. Dr. Chia-Cheng Hung, General Manager of SOFIVA, asserted, “This year, SOFIVA partnered with Formosa Cancer Foundation in providing BRCA1/2 Tests to many patients. We plan to make the tests accessible to even more patient groups in the future. Homologous recombination deficiency (HRD) genetic testing has also been a focus of R&D, particularly in gynecologic oncology (ovarian cancer, breast cancer, and endometrial cancer). We’re also preparing to launch the SOFIVA Tumor Mutational Burden (TMB) Test to facilitate adjuvant immunotherapy prediction and diagnosis.”

In recent years, SOFIVA has designed a series of precision genetic tests that target different cancer types and genetic mutations, including the BRCA1/2 Test, HRD Test, first-ever Genotyping Test for Endometrial Cancer, Prostate Cancer Genetic Testing Kit, and TMB Test, and committed itself to the expansion of cancer testing and precision medicine. A notable product is the most recent SOFIVA HRD Test, which is expected to give 50% of ovarian cancer patients access to targeted therapy, greatly enhancing targeted treatment and personalized care.

Genetic Testing Regimens to Uncover Targeted Breast, Ovarian, and Prostate Cancer Treatment

SOFIVA recently launched Taiwan's first-ever genetic testing regimen and BRCA1/2 genetic test designed to uncover targeted treatment for prostate cancer. The regimen aims to identify patients that would benefit from receiving PARP inhibitors. Testers will be able to receive their outcomes in as little as two weeks, helping them form effective treatment plans.

Dr. Chia-Cheng Hung, General Manager of SOFIVA, explained, “Everyone carries the BRCA1 and BRCA2 genes. When these genes do not function normally, like when the mutate, the carrier becomes prone to developing cancer, such as breast or ovarian cancer in women and prostate or male breast cancer in men.” Dr. Hung further elaborated, “Olaparib, a drug that targets cancers caused by BRCA1/2 gene mutations, was included in the NHI in November last year. This inclusion greatly increased market demand for genetic testing and expanded clinical treatment options.”